Non-Small-Cell Lung Cancer – Unmet Need – Detailed, Expanded Analysis – Metastatic Nonsquamous Non-Small-Cell Lung Cancer Without Driver Mutations (US/EU)
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the presence of molecular aberrations. While the minority of patients found positive for EGFR, ALK, BRAF, ROS1, c-MET, or RET aberrations are eligible to receive approved targeted agents, patients without driver mutations have limited treatment options. In the last decade, approval of multiple immune checkpoint inhibitors in the first-line setting has revolutionized the treatment of metastatic nonsquamous NSCLC without driver mutations. Immunotherapies such as Keytruda (Merck & Co.), Tecentriq (Roche / Genentech), Opdivo plus Yervoy (Bristol Myers Squibb), and Libtayo (Sanofi / Regeneron Pharmaceuticals) dominate the market as monotherapy and in combination with cytotoxic agents. However, a large population of patients with metastatic disease is unresponsive to immunotherapies; hence, there is a strong need for efficacious therapies in this patient setting.
QUESTIONS ANSWERED
- What are the drivers and constraints in the treatment of metastatic nonsquamous NSCLC without driver mutations?
- How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in the treatment of this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a hypothetical new first-line treatment for metastatic nonsquamous NSCLC without driver mutations?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 62 U.S. medical oncologists and 30 European medical oncologists fielded in February 2022
Key companies: Merck & Co., Bristol Myers Squibb, Roche / Genentech, Sanofi / Regeneron
Key drugs: Keytruda, Tecentriq, Opdivo, Yervoy, Libtayo
Table of contents
- Non-Small-Cell Lung Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Nonsquamous Non-Small-Cell Lung Cancer Without Driver Mutations (US/EU)
- Unmet need - Metastatic nonsquamous NSCLC without driver mutations - TPP simulator - May 2022
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed medical oncologists' prescribing decisions in metastatic nonsquamous NSCLC without driver mutations
- Importance of efficacy attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: United States
- Importance of efficacy attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: Europe
- Importance of safety and tolerability attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: United States
- Importance of safety and tolerability attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: Europe
- Importance of convenience of administration attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: United States
- Importance of convenience of administration attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: Europe
- Importance of nonclinical factors to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: United States
- Importance of nonclinical factors to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in metastatic nonsquamous NSCLC without driver mutations: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for metastatic nonsquamous NSCLC without driver mutations: United States
- Overall performance of key therapies for metastatic nonsquamous NSCLC without driver mutations: Europe
- Mean overall performance of key therapies for metastatic nonsquamous NSCLC without driver mutations: United States and Europe
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select efficacy attributes: United States
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select efficacy attributes: Europe
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select safety and tolerability attributes: United States
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select safety and tolerability attributes: Europe
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select convenience of administration attributes: United States
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select convenience of administration attributes: Europe
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select nonclinical attributes: United States
- Relative performance of key therapies for metastatic nonsquamous NSCLC without driver mutations across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in metastatic nonsquamous NSCLC without driver mutations
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for metastatic nonsquamous NSCLC without driver mutations on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for metastatic nonsquamous NSCLC without driver mutations on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key efficacy attributes in metastatic nonsquamous NSCLC without driver mutations: United States
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key efficacy attributes in metastatic nonsquamous NSCLC without driver mutations: Europe
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in metastatic nonsquamous NSCLC without driver mutations: United States
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in metastatic nonsquamous NSCLC without driver mutations: Europe
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key convenience of administration attributes in metastatic nonsquamous NSCLC without driver mutations: United States
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key convenience of administration attributes in metastatic nonsquamous NSCLC without driver mutations: Europe
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key nonclinical factors in metastatic nonsquamous NSCLC without driver mutations: United States
- Surveyed medical oncologistsu2019 ascribed level of unmet need across key nonclinical factors in metastatic nonsquamous NSCLC without driver mutations: Europe
- Key findings: unmet need in metastatic nonsquamous NSCLC without driver mutations and related indications
- Surveyed medical oncologists' ascribed level of unmet need in metastatic nonsquamous NSCLC without driver mutations and related indications: United States
- Surveyed medical oncologists' ascribed level of unmet need in metastatic nonsquamous NSCLC without driver mutations and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Saurabh Virdi, B.Tech., Lead Healthcare Research & Data Analyst, Oncology. Mr. Virdi has more than seven years working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, HIV, vaccines, specialty pharma, and rare diseases. Prior to joining Clarivate, he was an assistant project manager at DelveInsight Business Research LLP, where he was responsible for developing and delivering customized market and asset value forecasts. Before DelveInsight, he worked at WNS GSK Knowledge center and SmartAnalyst, where, as part of multifunctional teams, he helped clients’ decision making throughout the development journey from early-stage to marketed drugs. He obtained his bachelor’s degree in biotechnology from Delhi Technological University in India.